Has David Pou, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,187 in general payments to David Pou, MD across 59 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Pou, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Pou, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Pou, MD

Otolaryngology · Shreveport, LANPI 1992701395

Payments from drug & device makers

$1,187in general payments, 2019–2025

Across 59 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$638
Regeneron Healthcare Solutions, Inc.$162
Johnson & Johnson$158
GSK$125
Itamar Medical Inc$31
Sanofi-aventis U.S. LLC$19
plus $55 from 4 others

What the payments were for

Food & beverage$1,187100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	32	$638
Regeneron Healthcare Solutions, Inc.	11	$162
Johnson & Johnson	3	$158
GSK	6	$125
Itamar Medical Inc	2	$31
Sanofi-aventis U.S. LLC	1	$19
Medtronic	1	$17
Aerin Medical Inc.	1	$14
Merck	1	$13
Hikma Pharmaceuticals USA	1	$12

How this compares

$1,187 in reported general payments places this provider in the 40th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$113,304

Medicare patients

469

Services billed

1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	18	$1,914
Azelastine Hcl	31	$690
Ofloxacin	15	$430
Nystatin	12	$250
Cephalexin	38	$234
Montelukast Sodium	19	$216
Ipratropium Bromide	13	$208
Azithromycin	55	$197
Prednisone	61	$159
Mupirocin	20	$121
Fluconazole	17	$70
Levofloxacin	13	$54

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Shreveport

Maura CosettiShreveport$1.1M
Michael YimShreveport$113K
Cherie-Ann NathanShreveport$32K
Ameya AsarkarShreveport$8K
Vikas MehtaShreveport$8K
Roger BuiShreveport$5K
Jason CalligasShreveport$5K
Adam BlancherShreveport$4K
Rodrigo Martinez MonederoShreveport$3K
Karuna DewanShreveport$3K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →